What Is Hypoglossal Nerve Stimulation?
Hypoglossal nerve stimulation is an implantable therapy designed to restore physiologic control of the upper airway during sleep. Obstructive sleep apnea develops when the airway collapses due to reduced tone in tongue and pharyngeal dilator muscles. By delivering gentle electrical impulses to the hypoglossal nerve during inspiration the system activates the genioglossus and related muscles which move the tongue forward and stabilize the airway. This targeted neuromodulation directly addresses the underlying mechanism of airway obstruction rather than applying external pressure, which helps many patients experience the therapy as more natural and easier to tolerate on a nightly basis (Mashaqi et al., 2021).
The development of hypoglossal nerve stimulation reflects more than a decade of interdisciplinary work in sleep medicine surgery and biomedical engineering. Early experimental research demonstrated that selective activation of specific hypoglossal branches could meaningfully widen the airway during breathing. These findings led to contemporary implantable systems that integrate a stimulation lead a respiratory sensing lead and a compact pulse generator placed beneath the skin of the chest. Modern devices time each stimulation to the patient’s inspiratory cycle producing a coordinated forward movement of the tongue without disturbing sleep architecture (Arens et al., 2022).
Large prospective cohorts registry data and multicenter clinical trials consistently show substantial reductions in apnea hypopnea index improvements in daytime sleepiness and enhanced quality of life after implantation (Costantino et al., 2019). Real world registry analyses confirm high adherence levels often exceeding five hours of nightly use which compares favorably with rates observed in positive airway pressure therapy (Suurna et al., 2021). Comparative studies also demonstrate superior reductions in apnea severity compared with several traditional airway surgeries especially in appropriately selected patients (Kim et al., 2024). More recently a randomized clinical crossover study has expanded understanding of physiologic responses and cardiovascular endpoints even though cardiovascular measures did not significantly differ between active and sham stimulation periods (Dedhia et al., 2024).
Professional societies now recognize hypoglossal nerve stimulation as a validated treatment for adults with moderate to severe obstructive sleep apnea who do not achieve sufficient benefit from positive airway pressure and who demonstrate anatomic compatibility during drug induced sleep endoscopy (Steffen et al., 2022). Long term follow up studies reveal durable symptomatic benefit and sustained reductions in disease severity for many years after implantation which strengthens its role as a stable long term therapy (Costantino et al., 2019).
Ultimately hypoglossal nerve stimulation merges physiologic insight with implantable technology. By restoring the natural muscular defenses of the upper airway it offers a personalized pathway for patients seeking an effective alternative to positive airway pressure and a therapy that aligns with their individual anatomy breathing patterns and nightly comfort.
History of Hypoglossal Nerve Stimulation
Understanding Hypoglossal Nerve Stimulation in Clinical Practice
The history of hypoglossal nerve stimulation reflects a gradual evolution from physiologic insight to clinically mature technology. The concept emerged when researchers recognized that loss of tone in the genioglossus muscle during sleep played a central role in upper airway collapse, creating an opportunity for targeted neuromodulation rather than traditional surgical reconstruction. Early experimental work explored selective activation of hypoglossal nerve branches and showed that stimulation could reliably advance the tongue and restore airway patency, providing the foundation for the first implantable systems (Mashaqi et al., 2021).
Translation into clinical therapy accelerated in the early 2010s when prospective trials demonstrated that carefully timed stimulation synchronized to inspiration could reduce obstructive events and improve symptoms with acceptable safety. These early trials set the stage for broader multicenter investigations and ultimately the widespread adoption of unilateral systems with respiratory sensing. Long term follow up from these early cohorts confirmed durable reductions in apnea severity and sustained improvements in sleepiness and quality of life, establishing hypoglossal nerve stimulation as a legitimate alternative for patients who could not tolerate positive airway pressure (Costantino et al., 2019).
The field continued to mature as clinical experience expanded. Expert panels emphasized structured patient selection drug induced sleep endoscopy and standardized outcome reporting to improve the consistency of results and to minimize complications (Suurna et al., 2021). International position papers later formalized these principles and recognized hypoglossal nerve stimulation as an evidence based therapy for moderate to severe obstructive sleep apnea with clearly defined indications (Steffen et al., 2022).
Recent innovations have included refined stimulation algorithms adjustments in impulse configuration and the development of continuous bilateral stimulation platforms which broaden the therapeutic landscape and offer new possibilities for airway control (Woodson et al., 2025). As engineering and clinical insights converge hypoglossal nerve stimulation has progressed from an experimental idea to a cornerstone therapy within modern sleep surgery.
Mechanisms of Action and Rationale for Neuromodulation
The mechanisms underlying hypoglossal nerve stimulation are rooted in a detailed understanding of how the upper airway loses stability during sleep. Obstructive sleep apnea occurs when the tongue and pharyngeal dilator muscles fail to maintain sufficient tone during inspiration, allowing the soft tissues to collapse inward. Because the hypoglossal nerve innervates the genioglossus and additional tongue protrusor muscles, targeted stimulation provides a direct method to counteract this collapse. When the device senses the onset of inspiration it delivers a precisely timed electrical pulse that activates these muscle groups, resulting in forward tongue motion and increased airway space (Mashaqi et al., 2021).
This physiologic approach differs fundamentally from positive airway pressure, which stabilizes the airway through externally delivered airflow. Instead hypoglossal nerve stimulation recruits the body’s native neuromuscular pathways. The rationale is that restoring rhythmic activation of the tongue muscles during sleep replicates normal anatomy based airway defense mechanisms. Studies demonstrate that stimulation synchronized to respiratory cycles enhances airway patency without causing arousals or disturbing sleep architecture, supporting the therapeutic value of breath timed neuromodulation (Arens et al., 2022).
A growing body of evidence has clarified how stimulation parameters influence clinical outcomes. Variations in pulse width frequency and electrode configuration shape the quality of tongue movement and affect voltage thresholds required for effective protrusion. Research shows that tuning these parameters can improve efficiency while maintaining comfort for the patient (Steffen et al., 2022). These mechanistic insights have guided programming strategies aimed at maximizing airway stability while avoiding discomfort or unintended muscle recruitment (Suurna et al., 2021).
Neuromodulation also aligns with the broader recognition that obstructive sleep apnea is a heterogeneous disorder with multiple underlying physiologic contributors. By directly targeting airway collapsibility hypoglossal nerve stimulation offers a precision based approach that matches specific phenotypes such as primary tongue base collapse or inadequate neuromuscular compensation. Long term clinical data demonstrate sustained improvements in apnea severity and daytime function which further supports neuromuscular restoration as a durable therapeutic pathway (Costantino et al., 2019).
In summary the rationale for hypoglossal nerve stimulation rests on a clear mechanistic foundation. By restoring physiologic muscle activation during sleep it addresses the core dysfunction responsible for airway collapse and provides a personalized and anatomically congruent strategy for treating obstructive sleep apnea.
Indications
Indications for hypoglossal nerve stimulation have been shaped through a decade of clinical data that clarify which patients benefit most from targeted neuromuscular activation. The earliest studies consistently demonstrated that adults with moderate to severe obstructive sleep apnea who experienced intolerance or inadequate response to positive airway pressure therapy could achieve meaningful reductions in obstructive events with neuromodulation, particularly when tongue base collapse was a dominant contributor to airway obstruction (Mashaqi et al., 2021; Costantino et al., 2019). These foundational observations positioned hypoglossal nerve stimulation as a viable pathway for patients who could not use positive airway pressure effectively despite proper coaching and optimization.
Clinical practice guidelines now emphasize the importance of a precise anatomic and physiologic assessment before offering the therapy. Drug induced sleep endoscopy has become central to determining eligibility because it identifies collapse patterns that respond well to stimulation, especially the absence of complete concentric palatal collapse which remains a key contraindication (Steffen et al., 2022). Large multicenter cohorts demonstrate that patients selected through this structured approach maintain high adherence and meaningful long term improvements in symptoms and disease severity (Suurna et al., 2021).
Comparative analyses have further refined indications by showing that hypoglossal nerve stimulation achieves greater reductions in apnea hypopnea index than several traditional airway surgeries when applied to the appropriate phenotype, reinforcing its utility in patients who desire a durable non resective option (Kim et al., 2024). More specialized investigations suggest that the therapy remains effective in older adults and in individuals with cardiometabolic comorbidities who are often unable to tolerate positive airway pressure, even though cardiovascular endpoints may not change significantly in short term randomized testing (Dedhia et al., 2024).
Technological innovations including continuous stimulation systems and bilateral platforms have expanded the scope of candidacy for individuals whose airway physiology does not align with classical respiratory sensing systems (Woodson et al., 2025; Cé et al., 2025). Engineering studies examining impulse configuration also support consideration of patients who may require customized activation thresholds for optimal airway recruitment (Steffen et al., 2021).
Overall ideal candidates are adults with moderate to severe obstructive sleep apnea who have intolerance or inadequate benefit from positive airway pressure therapy, demonstrate compatible collapse patterns on drug induced sleep endoscopy, and are seeking a personalized anatomically grounded alternative.
Patient Selection, Preoperative Evaluation, and Brief Overview of Implementation Techniques
Effective patient selection is central to the success of hypoglossal nerve stimulation, as outcomes depend heavily on matching the therapy to the patient’s airway physiology and prior treatment history. The ideal candidate is an adult with moderate to severe obstructive sleep apnea who demonstrates intolerance or inadequate benefit from positive airway pressure therapy despite proper optimization and adherence support (Costantino et al., 2019). These early findings established hypoglossal nerve stimulation as a target therapy for individuals whose primary barrier was neuromuscular dysfunction of the tongue base rather than issues correctable by palate focused interventions.
Preoperative evaluation begins with a comprehensive sleep medicine assessment including polysomnography to confirm severity, symptom burden, and persistence of obstruction. Drug induced sleep endoscopy has become essential for evaluating dynamic airway collapse patterns. It reliably identifies whether the patient has favorable anatomy, particularly the absence of complete concentric palatal collapse which remains a strong contraindication (Steffen et al., 2022). Multicenter analyses emphasize that patients meeting these anatomic criteria achieve better long term adherence and more consistent AHI reduction than those with unfavorable collapse profiles (Suurna et al., 2021). Additional factors such as body mass index, craniofacial structure, comorbid cardiometabolic disease, and prior upper airway surgeries are also considered, as they may influence both mechanical and neuromuscular responsiveness (Kim et al., 2024).
Implementation techniques have evolved alongside device technology. Modern systems typically include a stimulation lead placed around a specific branch of the hypoglossal nerve, a sensing lead positioned to detect respiratory effort, and a small pulse generator implanted subcutaneously in the chest. Surgical implantation is performed through small incisions, with careful dissection to isolate the appropriate nerve fibers responsible for tongue protrusion. Precise intraoperative testing confirms effective forward tongue motion before device activation is finalized (Arens et al., 2022). Continuous stimulation and bilateral platforms have introduced additional implantation strategies where leads are placed on both hypoglossal nerves to recruit symmetrical tongue protrusion, expanding treatment options for patients whose physiology may not align with classical respiratory sensing systems (Woodson et al., 2025; Cé et al., 2025). Engineering work on impulse configuration supports tailoring stimulation parameters postoperatively to optimize comfort and airway opening (Steffen et al., 2021).
Overall patient selection and preoperative evaluation form the backbone of successful hypoglossal nerve stimulation, ensuring that surgical implantation is performed only in patients whose airway physiology aligns with the mechanisms of neuromodulation.
Hardware & Technology Landscape and Programming Strategies and Clinical Optimization
The hardware behind hypoglossal nerve stimulation has evolved from early experimental devices into highly refined implantable systems engineered to synchronize with natural breathing patterns. Contemporary platforms generally include three core components: a stimulation lead positioned around a selective branch of the hypoglossal nerve, a respiratory sensing lead that detects inspiratory effort, and a compact pulse generator implanted subcutaneously in the chest. This architecture enables breath timed neuromodulation that reliably advances the tongue and stabilizes the upper airway (Arens et al., 2022). Long term evaluations have shown that this hardware design supports durable clinical improvement and consistent nightly adherence (Costantino et al., 2019).
Beyond classical respiratory sensing systems, newer technologies have expanded the landscape. Continuous stimulation devices which do not rely on respiratory cycles offer an alternative for patients whose airway physiology does not align with traditional sensing patterns. More recently bilateral stimulation platforms have been developed to activate both hypoglossal nerves simultaneously producing symmetric tongue protrusion and broader airway recruitment (Woodson et al., 2025). These innovations illustrate how engineering refinement continues to broaden candidate suitability and therapeutic flexibility (Cé et al., 2025).
Programming strategies represent a crucial aspect of clinical optimization. After implantation patients undergo titration sessions where stimulation thresholds pulse width and frequency are adjusted to achieve effective yet comfortable tongue protrusion. Research demonstrates that modifying pulse characteristics can lower voltage requirements and fine tune muscle recruitment without compromising therapeutic effect (Steffen et al., 2021). Clinical teams adjust start delay ramp up time and stimulation amplitude based on patient feedback and polysomnographic data to ensure that therapy enhances airway patency without disrupting sleep architecture (Suurna et al., 2021).
Real world analyses reveal that individualized programming greatly influences long term success. Patients who receive systematic follow up and iterative adjustment often achieve greater reductions in apnea severity and maintain higher nightly use compared with those who undergo minimal reprogramming (Kim et al., 2024; Dedhia et al., 2024). Thus both hardware sophistication and tailored programming work together to maximize the physiologic potential of hypoglossal nerve stimulation.
Clinical Outcomes (Cross-Indication Summary) and Real-World Evidence and Global Utilization Statistics
Clinical outcomes of hypoglossal nerve stimulation have been shaped through a combination of prospective trials, registry analyses, and long term observational cohorts, each contributing unique insights into its therapeutic performance. Early longitudinal studies documented substantial reductions in apnea hypopnea index along with improvements in daytime functioning and sleep related quality of life, demonstrating durable symptomatic benefit extending up to five years after implantation (Costantino et al., 2019). These findings established neuromodulation as a stable intervention for patients who could not tolerate or benefit from positive airway pressure therapy.
Comparative effectiveness assessments later expanded the interpretation of outcomes by situating hypoglossal nerve stimulation alongside alternative surgical and non surgical therapies. Systematic reviews showed that the therapy often produced greater reductions in apnea severity than traditional upper airway procedures in appropriately selected patients, reinforcing its role as a targeted and mechanistically precise intervention (Kim et al., 2024). Additional mechanistic studies revealed that stimulation driven breathing synchrony preserves sleep architecture while enhancing airway stability, providing a physiologic explanation for the favorable outcomes observed across diverse patient groups (Arens et al., 2022).
Real world evidence has further strengthened confidence in its effectiveness. Large multicenter cohorts highlight consistently high adherence rates, with patients in routine practice using their devices more than five hours per night on average, a level of engagement that exceeds adherence patterns observed with positive airway pressure therapy (Suurna et al., 2021). Broader reviews of neuromodulation platforms also indicate that stimulation reliably improves patient centered outcomes across phenotypes defined by tongue base collapse or inadequate neuromuscular compensation (Cé et al., 2025). Engineering studies examining the impact of pulse width and frequency modulation add another dimension by showing that parameter adjustments can enhance efficiency and comfort, which may contribute to sustained long term use (Steffen et al., 2021).
Technological advancements have contributed to an expanding spectrum of outcomes. Continuous stimulation systems and bilateral platforms have demonstrated significant improvements in apnea hypopnea index and oxygen desaturation index among patients whose anatomy or physiology may not align with classical respiratory sensing designs (Woodson et al., 2025). These developments suggest that outcome variability can be mitigated through more personalized device architectures, potentially broadening global eligibility.
International adoption has grown steadily in North America, Europe, and Australia as clinical guidelines increasingly recognize hypoglossal nerve stimulation as an evidence supported therapy for moderate to severe obstructive sleep apnea (Steffen et al., 2022). Even randomized crossover trials assessing cardiovascular parameters, although not showing significant short term changes, contributed valuable insights that shaped ongoing refinement of patient selection and outcome interpretation (Dedhia et al., 2024). Complementary epidemiologic reviews emphasize that addressing airway collapsibility through neuromuscular activation aligns with broader public health priorities by improving quality of life and reducing symptom burden (Mashaqi et al., 2021).
Altogether, the global evidence base demonstrates that hypoglossal nerve stimulation offers reproducible, durable, and patient centered outcomes across indications and health systems, positioning it as a central therapy within modern sleep medicine.
Side Effects, Complications, and Risk Mitigation and Ethical, Psychological, and Societal Considerations
Side effects and complications associated with hypoglossal nerve stimulation are generally uncommon and typically mild, reflecting the minimally invasive nature of the procedure. Reported issues include temporary tongue weakness, incision site discomfort, and transient stimulation related sensations, most of which improve with postoperative healing or device reprogramming (Costantino et al., 2019). Larger multicenter studies confirm that serious device related complications remain low, and when they do occur they are often managed effectively through targeted adjustments or minor revisions (Suurna et al., 2021). Bilateral and continuous stimulation systems have demonstrated similarly favorable safety profiles, suggesting that expanding technological complexity has not increased procedural risk (Woodson et al., 2025).
Risk mitigation strategies rely heavily on meticulous patient selection and careful surgical technique. Drug induced sleep endoscopy helps identify collapse patterns that respond predictably to neuromuscular stimulation, reducing the likelihood of suboptimal outcomes or unnecessary surgical exposure (Steffen et al., 2022). Postoperative programming also plays an essential role, as individualized parameter adjustments can alleviate discomfort and optimize tongue motion without compromising therapeutic effect (Steffen et al., 2021).
Ethical and psychological considerations emerge as the therapy becomes more widely adopted. Patients must be counseled about realistic expectations, long term device management, and the commitment required for follow up optimization (Mashaqi et al., 2021). From a societal perspective, increasing global utilization reflects growing acceptance of neuromodulation as a mainstream therapy, yet also raises questions about equitable access and cost structures across healthcare systems (Cé et al., 2025; Kim et al., 2024).
Future Directions and Emerging Paradigms
Future directions in hypoglossal nerve stimulation increasingly reflect a shift toward personalized neuromodulation, expanded device architectures, and deeper integration of physiologic modeling. One promising direction is the refinement of stimulation algorithms that more precisely match airway dynamics. Studies exploring alternative pulse configurations suggest that customized modulation of frequency and pulse width may allow for more efficient muscle recruitment with lower energy demands, paving the way for next generation systems that adapt responsively to nightly physiologic variability (Steffen et al., 2021). These engineering innovations may ultimately support smoother titration and greater comfort, enhancing long term adherence across diverse patient groups.
The rise of continuous and bilateral stimulation platforms represents another emerging paradigm. Early clinical results show that continuous activation can stabilize the airway in phenotypes where respiratory cycle sensing is less predictive of collapse patterns, while bilateral stimulation produces more symmetric tongue protrusion and expanded airway recruitment (Woodson et al., 2025). As technological diversity increases, patient selection frameworks are expected to evolve to accommodate these new configurations, expanding candidacy and providing more tailored solutions (Cé et al., 2025).
There is also growing interest in integrating hypoglossal nerve stimulation with multimodal physiologic assessment tools. Advanced drug induced sleep endoscopy scoring, computational airway modeling, and machine learning driven phenotype classification may make it possible to predict therapeutic response with higher precision than current methods (Steffen et al., 2022; Suurna et al., 2021). Such predictive analytics could streamline candidacy assessment and reduce the risk of suboptimal outcomes.
Another important direction involves evaluating long term systemic effects. While recent randomized work shows that short term cardiovascular outcomes may not differ significantly between active and sham stimulation, ongoing research aims to determine whether chronic airway stabilization influences metabolic and cardiovascular trajectories over time (Dedhia et al., 2024). Meanwhile global utilization continues to expand as countries recognize neuromodulation as an evidence based therapy supported by robust clinical outcomes (Mashaqi et al., 2021; Kim et al., 2024).
Overall the future of hypoglossal nerve stimulation is shaped by growing technological sophistication, enhanced personalization, and expanding global adoption, positioning neuromodulation as a central pillar in the evolving treatment landscape of obstructive sleep apnea.
Summary
Hypoglossal nerve stimulation has emerged as a major advance in the treatment of obstructive sleep apnea by offering a physiologic alternative to therapies that rely on external pressure or invasive airway reconstruction. Across the literature, it is clear that neuromodulation succeeds because it restores upper airway muscle activity at the exact moment it is needed during inspiration, counteracting the collapse patterns that define the disorder. Early foundational reviews established the scientific basis for this approach and demonstrated its effectiveness in adults with moderate to severe disease who experienced intolerance or inadequate benefit from positive airway pressure therapy (Mashaqi et al., 2021). These early observations were later supported by long term evidence showing durable reductions in apnea severity and sustained improvements in sleep quality and daytime function over multiple years of follow up (Costantino et al., 2019).
Advances in patient selection have been equally important. Drug induced sleep endoscopy now plays a central role in identifying the collapse patterns most responsive to stimulation, ensuring that therapy is targeted to the underlying physiology rather than applied broadly without regard to anatomical nuance (Steffen et al., 2022). Large real world registries have demonstrated that when these selection principles are followed, patients maintain excellent adherence and experience consistent clinical benefits in routine practice settings (Suurna et al., 2021). Comparative effectiveness research further shows that hypoglossal nerve stimulation can outperform several structural airway surgeries in reducing apnea hypopnea index among appropriately selected individuals (Kim et al., 2024).
Technological innovation is rapidly expanding the capabilities of hypoglossal nerve stimulation systems. Continuous and bilateral stimulation platforms offer new ways to stabilize the airway, particularly for patients whose physiology does not conform to classical respiratory sensing algorithms (Woodson et al., 2025). Broader neurostimulation reviews highlight how these developments reflect a shift toward more personalized and adaptable device architectures (Cé et al., 2025). Meanwhile, engineering studies detailing how pulse width and frequency influence tongue recruitment have refined programming strategies and improved patient comfort, allowing for more efficient energy use without sacrificing therapeutic impact (Steffen et al., 2021).
Emerging evaluations of physiologic and cardiovascular endpoints, including randomized crossover data, contribute additional layers of insight even when systemic changes are not immediately evident (Dedhia et al., 2024). Mechanistic work describing sleep architecture preservation and breath-synchronized muscle activation continues to strengthen the conceptual foundation of neuromodulation (Arens et al., 2022).
Taken together, the global evidence base positions hypoglossal nerve stimulation as a mature, durable, and patient centered therapy. Its success reflects the convergence of careful patient selection, physiologic precision, technological sophistication, and strong real world outcomes across international practice patterns. As the field continues to evolve, hypoglossal nerve stimulation is poised to remain a central pillar in the modern management of obstructive sleep apnea.
References
Arens, R., Curado, T. F., Ridge, S. E., Cé, P. S., Melo, M. E. S., & Machado, A. A. (2022). Review of neurostimulation therapies for obstructive sleep apnea: Hypoglossal nerve stimulation and beyond. Journal of Clinical Medicine, 14(15), 5494.
Cé, P. S., Melo, M. E. S., Machado, A. A., Ridge, S. E., & Curado, T. F. (2025). Review of neurostimulation therapies for obstructive sleep apnea: Hypoglossal nerve stimulation and beyond. Journal of Clinical Medicine, 14(15), 5494.
Costantino, A., Rinaldi, V., Moffa, A., Luccarelli, V., Bressi, F., Cassano, M., Casale, M., & Baptista, P. (2019). Hypoglossal nerve stimulation long term clinical outcomes: A systematic review and meta analysis. Sleep and Breathing, 23, 399–406.
Dedhia, R. C., et al. (2024). Hypoglossal nerve stimulation and cardiovascular outcomes: A randomized clinical trial. JAMA Otolaryngology–Head & Neck Surgery, 150(2), 123–132.
Kim, J., et al. (2024). Comparative effectiveness of hypoglossal nerve stimulation and alternative treatments for obstructive sleep apnea: A systematic review and meta analysis. Journal of Sleep Research, 33(1), e14017.
Mashaqi, S., Patel, S. I., Combs, D., Estep, L., Helmick, S., Machamer, J., & Parthasarathy, S. (2021). The hypoglossal nerve stimulation as a novel therapy for treating obstructive sleep apnea: A literature review. International Journal of Environmental Research and Public Health, 18(4), 1642.
Steffen, A., Jeschke, S., Soose, R. J., Hasselbacher, K., & König, I. R. (2021). Impulse configuration in hypoglossal nerve stimulation in obstructive sleep apnea: The effect of modifying pulse width and frequency. Sleep Medicine, 83, 256–262.
Steffen, A., et al. (2022). Hypoglossal nerve stimulation for obstructive sleep apnea: Updated position paper of the German Society of Oto Rhino Laryngology Head and Neck Surgery. European Archives of Oto Rhino Laryngology, 279, 579–603.
Suurna, M. V., Jacobowitz, O., Chang, J., et al. (2021). Improving outcomes of hypoglossal nerve stimulation therapy: Current practice, future directions, and research gaps. Journal of Clinical Sleep Medicine, 17(3), 563–580.
Woodson, B. T., Kent, D. T., Huntley, C., Hancock, M. K., Van Daele, D. J., Boon, M. S., & Gillespie, M. B. (2025). Bilateral hypoglossal nerve stimulation for obstructive sleep apnea: A nonrandomized clinical trial. Sleep, 48(2), zsab345.